Suppr超能文献

人类首例无缺血肾脏移植病例。

The First Case of Ischemia-Free Kidney Transplantation in Humans.

作者信息

He Xiaoshun, Chen Guodong, Zhu Zebin, Zhang Zhiheng, Yuan Xiaopeng, Han Ming, Zhao Qiang, Zheng Yitao, Tang Yunhua, Huang Shanzhou, Wang Linhe, van Leeuwen Otto B, Wang Xiaoping, Chen Chuanbao, Mo Liqiu, Jiao Xingyuan, Li Xianchang, Wang Changxi, Huang Jiefu, Cui Jun, Guo Zhiyong

机构信息

Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Guangzhou, China.

出版信息

Front Med (Lausanne). 2019 Dec 11;6:276. doi: 10.3389/fmed.2019.00276. eCollection 2019.

Abstract

Ischemia-reperfusion injury (IRI) has been considered an inevitable event in organ transplantation since the first successful kidney transplant was performed in 1954. To avoid IRI, we have established a novel procedure called ischemia-free organ transplantation. Here, we describe the first case of ischemia-free kidney transplantation (IFKT). The kidney graft was donated by a 19-year-old brain-dead donor. The recipient was a 47-year-old man with end-stage diabetic nephropathy. The graft was procured, preserved, and implanted without cessation of blood supply using normothermic machine perfusion. The graft appearance, perfusion flow, and urine production suggested that the kidney was functioning well-during the whole procedure. The creatinine dropped rapidly to normal range within 3 days post-transplantation. The levels of serum renal injury markers were low post-transplantation. No rejection or vascular or infectious complications occurred. The patient had an uneventful recovery. This paper marks the first case of IFKT in humans. This innovation may offer a unique solution to optimizing transplant outcomes in kidney transplantation.

摘要

自1954年首例肾移植成功以来,缺血再灌注损伤(IRI)一直被认为是器官移植中不可避免的事件。为避免IRI,我们建立了一种名为无缺血器官移植的新方法。在此,我们描述首例无缺血肾移植(IFKT)病例。肾移植物由一名19岁的脑死亡供体捐赠。受者是一名47岁患有终末期糖尿病肾病的男性。使用常温机器灌注在不中断血液供应的情况下获取、保存并植入移植物。移植物外观、灌注流量和尿液生成表明肾脏在整个过程中功能良好。移植后3天内肌酐迅速降至正常范围。移植后血清肾损伤标志物水平较低。未发生排斥反应、血管或感染并发症。患者恢复顺利。本文标志着人类首例IFKT病例。这一创新可能为优化肾移植的移植结果提供独特的解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8292/6917615/54f194a8ebff/fmed-06-00276-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验